Overview

Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety and tolerability of the drug Anti-IL-20 in subjects with rheumatoid arthritis.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S